Trump UNLEASHES Risky Psychedelic Drugs

President Trump signs executive order fast-tracking risky psychedelic drugs like ibogaine for veterans, bypassing deep state FDA hurdles despite known cardiac deaths.

Story Highlights

Trump allocates $50 million through ARPA-H to match state funding for psychedelic research targeting PTSD and addiction in veterans.
Directs FDA and DEA to open Right to Try pathways for eligible patients without rescheduling Schedule I substances like ibogaine.
Removes federal research barriers amid a mental health crisis affecting over 14 million Americans, prioritizing innovation over bureaucracy.
Ibogaine, used abroad for PTSD, faces cardiac risks, including 27 deaths, yet gains explicit federal attention.
Builds on Texas state trials and Trump’s 2018 Right to Try law, empowering states and patients against federal overreach.

Trump’s Bold Move for Veterans

President Donald Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate research into psychedelic drugs for serious mental illnesses. The order targets PTSD, depression, addiction, and traumatic brain injuries, especially among veterans suffering high suicide rates.

It allocates $50 million via ARPA-H to match state investments, fostering clinical trials without reclassifying Schedule I drugs. This action responds to veteran advocates frustrated by unregulated clinics abroad.

FDA and DEA must establish access pathways under the Right to Try Act for eligible patients, including those with terminal conditions. The order prioritizes psychedelics with Breakthrough Therapy designations, issuing National Priority Vouchers to cut red tape.

Trump emphasized this as a scientific step against the mental health crisis impacting 14 million Americans, cutting through bureaucratic delays that block promising treatments.

Ibogaine’s Promise and Perils

Ibogaine, derived from the African Tabernanthe iboga shrub, shows potential for interrupting addiction and treating PTSD based on a 2023 review of 24 studies involving 705 people. A 2024 Stanford study found it safe for veterans when combined with magnesium, reducing withdrawal and cravings.

However, cardiac toxicity, including QT prolongation, arrhythmias, and 27 deaths, raises alarms from NIDA Director Nora Volkow. Americans currently travel to Mexico or Caribbean clinics for unregulated access.

The executive order explicitly names ibogaine twice, directing reviews despite lacking Phase I trials. This contrasts with MDMA precedents and state efforts like Texas’s 2025 ibogaine consortium.

Experts like Harvard’s Glenn Cohen and Mason Marks call the focus surprising given safety gaps, yet note it builds on veteran needs and removes research impediments without immediate rescheduling.

Trump signs order to speed review of psychedelics, including the controversial drug ibogainehttps://t.co/1ndcZ6JYjv pic.twitter.com/QRget6qwpP

— 1010 WINS on 92.3 FM (@1010WINS) April 18, 2026

Stakeholders and Power Shifts

Key players include Trump directing policy, White House and HHS managing $50 million funds, and FDA/DEA implementing pathways. Texas leads with state-funded trials, prompting federal matching.

Veterans push for options beyond bans, while critics urge caution on unproven risks. This dynamic empowers states and patients, countering federal resistance rooted in outdated Schedule I classifications from the 1970s.

Trump signs order to speed review of psychedelics, including the controversial drug ibogainehttps://t.co/ZdpbVpAqi5

— FOX19 NOW (@FOX19) April 19, 2026

The order mandates HHS and FDA collaboration with the VA and private sector to boost trial participation. Attorney General reviews follow Phase 3 success for potential rescheduling.

Institutions like Stanford, Harvard, and Johns Hopkins study psychedelics, validating promise amid a crisis where traditional therapies fail. This reflects shared frustrations across political lines with government elites prioritizing jobs over American lives.

Impacts on Mental Health and Beyond

Short-term, $50 million spurs trials and Right to Try access for terminal veterans, contrasting overseas risks with regulated paths. Long-term, successful data could lead to FDA approvals, addressing PTSD gaps for military heroes.

Economically, it boosts biotech; socially, tackles 14 million cases; politically, cements Trump’s innovation legacy and state-federal synergy against deep state inertia.